It does seem that everyone is rightly asking about the significance of the bone scan data especially when following metastatic prostate cancer by bone scan alone if fraught with inaccuracy:
Findings on bone scans not in correlation with clinical findings and serum AP levels are mostly misleading. Use of bone scans in conjunction with serum AP levels and most probably with prostate-specific antigen and CPS is the most reliable and therefore treatment modality changes should not be based on bone scans only.
But in EXEL's case, we have improvement in alk phos and anemia and bone pain......hence, the findings on bone scan are in synch with the laboratory improvements (other than PSA).
I guess we will need to wait for the ASCO meeting to learn more first week in June.......unless they announce a partner in interim.
Market Data 
Markets 
AI
